Cubresa

Cubresa operates in the specialized PET/MRI and molecular-imaging segment rather than the broad diagnostic-imaging market. Its differentiation is built around removable PET insert systems that can be integrated with existing MRI scanners, reducing the need for customers to purchase a fully dedicated PET/MR platform. BrainPET targets clinical and translational brain imaging across 1.5T, 3T, and 7T MRI environments, while NuPET Insert System and NuPET Bio address flexible preclinical research, including imaging in BSL-3 laboratories. The February 2025 agreement with Siemens Healthineers adds credibility and potential distribution leverage, and the August 2026 FDA 510(k) clearance expands the company’s relevance to clinical customers. Cubresa’s apparent market position is therefore best understood as a focused specialist: it emphasizes modularity, portability, MRI compatibility, and research-to-clinic applicability.

Cubresa’s trajectory shows a gradual progression from early-stage imaging technology development to clinical commercialization. Founded in 2011, the company recorded a $500,000 seed round on July 1, 2013, with Manitoba Knights identified as the investor. Its early technology work included an imaging-cloak patent announcement in 2016 and the development of MR-compatible PET inserts for both clinical and preclinical use. Organizational expansion became more visible in 2021 and 2022, when the company added senior operations, research and development, sales, finance, and quality leadership; Matt Hudson and Mayra Alejo formally joined in May 2022. Product validation accelerated with the first BrainPET installation at Lawson Health Research Institute in May 2023. These developments suggest movement toward clinical adoption, but the limited disclosed financing history, absence of public revenue figures, and lack of documented employee-growth metrics make the pace and scale of expansion difficult to quantify.